Navigating a Changing Landscape in TNBC: Pharmacist-Focused Strategies in the Era of Immunotherapy
Symposium attendees will gain insights into the molecular heterogeneity and diverse clinical features of TNBC, a condition which comprises 15-20% of all breast cancer cases, and has historically had limited treatment options, been associated with earlier age of onset, more aggressive disease course, and poorer prognosis. Attendees will also review the current state of immunotherapy research in TNBC, including completed and ongoing clinical trials across various stages of the disease continuum, the approval of emerging agents and indications throughout the treatment calculus, and prospective avenues of research focus, such as the identification of predictive novel biomarkers to help guide treatment decisions. Finally, using an interactive, case-based approach, this symposium will comprehensively evaluate current challenges in TNBC management and examine adaptive strategies that managed care professionals and specialty pharmacists can employ to optimize patient outcomes in the era of immunotherapy.
Presented by Creative Educational Concepts and supported through an independent educational grant from Merck & Co., Inc.
This activity is designed to meet the educational needs of pharmacy directors, pharmacists, physicians, medical directors, and other managed care professionals attending the AMCP Managed Care & Specialty Pharmacy Annual Meeting 2020.
- Discuss the molecular heterogeneity of triple-negative breast cancer (TNBC) and examine the diverse clinical features that impact treatment.
- Appraise the current state of the TNBC treatment paradigm and investigate emerging, top-line trial data regarding the safety and efficacy profiles of immune checkpoint inhibitors.
- Explore the importance of identifying novel biomarkers in TNBC to help guide treatment decisions.
- Using a case-based approach, evaluate clinical challenges in TNBC management and discuss adaptive ways the oncology pharmacist can optimize patient outcomes in the era of immunotherapy.
6:30 PM–6:40 PM
Welcome and Introductions/Pre-test
6:40 PM-6:55 PM
Examining a Complex Condition: The Molecular and Pathophysiologic Features that Impact TNBC Management
6:55 PM-7:25 PM
Where We’ve Been, Where We’re Going: An Exploration of Current Paradigms and Prospective Avenues
7:25 PM–7:50 PM
Revolutionizing TNBC Outcomes with Immunotherapy: The Pivotal Role of Specialty Pharmacists and Managed Care Professionals
7:50 PM–8:00 PM
Conversations with the Experts and Audience Q&A/Post-test
Sandra Cuellar, PharmD, BCOP (Activity Chair)
Clinical Oncology Pharmacist
Clinical Assistant Professor
Director, PGY-2 Oncology
University of Illinois Hospital & Health Sciences System
Sandra Cuellar, PharmD, BCOP is a Clinical Associate Professor in the Department of Pharmacy Practice at the University of Illinois at Chicago (UIC) College of Pharmacy. Dr. Cuellar has been active in the field of hematology/oncology for 17 years. She is the Coordinator and Clinical Associate Professor for Oncology Therapeutics. Dr. Cuellar received her Bachelor of Liberal Arts from Augustana College in Rock Island, Illinois, followed by her PharmD from the UIC College of Pharmacy. She then completed a Pharmacy Practice Residency at University of Kentucky Chandler Medical Center. Following her residency, she completed a specialty oncology residency at MD Anderson Cancer Center in Houston, Texas. She currently is the Clinical Pharmacist in the Outpatient Cancer Center, Director of the Oncology Specialty Residency Program, and Vice-Chair of the Institutional Review Board at UIC. Dr. Cuellar is an Editor-at-Large for the Journal of Hematology Oncology Pharmacy and is involved in research, consulting, and publications in the field of hematology/oncology. She has given multiple national and international presentations on cardio-oncology, supportive care, and oncology therapeutics. In addition, Dr. Cuellar serves as an ASHP oncology surveyor and continues to serve on multiple committees for the Hematology/Oncology Pharmacy Association.
Rita Nanda, MD
Hematology and Oncology (Cancer)
Associate Professor of Medicine
Director, Breast Oncology Program
The University of Chicago Medicine
Rita Nanda, MD is an Associate Professor of Medicine and Director of Breast Oncology at The University of Chicago. Dr. Nanda earned her undergraduate degree in Chemical Engineering from the Massachusetts Institute of Technology and her Medical Degree from The University of Chicago, Pritzker School of Medicine. She subsequently completed her Residency in Internal Medicine and her Fellowship in Hematology/Oncology at The University of Chicago.
Dr. Nanda’s research interests include identifying novel treatments for the management of breast cancer, particularly triple-negative disease. She leads The University of Chicago’s clinical and translational breast cancer research efforts, and serves as a Principal Investigator (PI) for the Translational Breast Cancer Research Consortium (TBCRC) and the I-SPY2 Clinical Trial Network. She is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, and the Society for Immunotherapy of Cancer.
Dr. Nanda has authored numerous scientific publications and book chapters, including one of the first reports of immune checkpoint inhibitor therapy for triple-negative breast cancer. She has been invited to present her research at national and international conferences. In recognition of her leadership and research contributions in developing novel strategies for women with breast cancer, she was awarded the 2014 NCI Cancer Clinical Investigator Team Leadership Award. She has been selected to serve on a number of international committees, including the Breast Immuno-Oncology (BIO) Taskforce of the National Cancer Institute (NCI) Breast Cancer Steering Committee (BCSC), the Breast International Group-North American Breast Cancer (BIG-NABCG) Taskforce on Immunotherapy for Breast Cancer, and the BIG-NABCG Taskforce on Tailoring Immunotherapy for Triple-Negative Breast Cancer.
Dr. Nanda’s research has been funded by the NIH, The Department of Defense Breast Cancer Research Program, the Doris Duke Charitable Foundation, the Susan G. Komen Foundation, and the Metastatic Breast Cancer Network. She currently serves as a co-PI on The University of Chicago’s Interdisciplinary Cancer Health Disparities P20 SPORE and a Breast Cancer Research Foundation Grant investigating the role of androgen receptor (AR) blockade in AR positive triple-negative breast cancer.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity. Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in
Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.
Bryan Taylor, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.
Sandra Cuellar, PharmD, BCOP—has disclosed that she is on the speakers’ bureau for Eisai and Genentech.
Rita Nanda, MD—has disclosed that she is a consultant for Aduro, Clovis, Daiichi Sankyo, Inc., Genentech, MacroGenics, Merck, and Pfizer. She receives grant/research support from AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, OBI Pharm, Inc., Odonate Therapeutics, Pfizer, and Seattle Genetics. She receives financial support from G1 Therapeutics (DSMB).
Jason Bergsbaken, PharmD, BCOP—has no relevant financial relationships to disclose in relation to the content of this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit JA0007101-0000-20-009-L01-P
- 1.50 ACPE PharmacyIn support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This knowledge-based activity is approved for 1.50 contact hour (0.15 CEUs) of continuing pharmacy education credit JA0007101-0000-20-009-L01-P
- 1.50 AMA PRA Category 1 Credit™In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Participation